Boiron reports sales of €534 million for the 2022 financial year, up 17.4% on 2021.

At the same time, operating income is up 35.5% to €63 million, while net income (Group share) stands at €44.6 million, up 56.4% year-on-year.

In 2023, the Group's sales growth will potentially be impacted by the decline in sales of COVID tests, by tension over raw material and energy supplies, and by the geopolitical situation in certain regions of the world, Boiron believes.

We continue to put all our energy and determination into ensuring that every patient in the world can benefit from homeopathy and our other healthcare solutions, in order to participate in the development of a more humane, efficient and sustainable healthcare system", concludes the company.


Copyright (c) 2023 CercleFinance.com. All rights reserved.